Motif Neurotech receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI for Treatment-Resistant Depression
Neurava Awarded $4 Million NIH Blueprint Optimizer Award to Develop SUDEP Risk Stratification Algorithm